The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters

Cover Page

Cite item

Full Text

Abstract

Background. Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease; it is characterized by left ventricular (LV) hypertrophy that cannot be explained by hemodynamic causes. It is believed that sarcomere dysfunction underlies the pathogenesis of this disease, however, only half of patients with the HCM phenotype have mutations in sarcomere-encoding genes. HCM is distinguished by both high genetic and clinical heterogeneity and therefore more studies are seeking to investigate a regulation of gene expression in HCM and how the abnormalities in this process can affect disease phenotype. One of the levels of regulation of gene expression – a post-transcriptional level – is mediated by short non-coding microRNAs that inhibit protein synthesis.

Aim. To identify the correlations between levels of circulating microRNAs, previously shown to be associated with HCM, and clinical parameters of HCM patients.

Materials and methods. Correlation analysis of miR-499a-5p, miR-454 and miR-339-5p plasma levels and clinical parameters of 33 HCM patients, examined from 2019 to 2021, has been performed.

Results. Variants in HCM-associated genes were found in 49% of patients. There were no clinical differences between genotype-positive and genotype-negative patients. MiR-499a-5p level correlated with LV ejection fraction, miR-454 level – with LV diastolic function parameters and miR-339-5p level – with left atrium dimension.

Conclusion. Levels of certain circulating microRNAs correlate with echocardiographic parameters in HCM patients.

About the authors

Maria V. Pisklova

Chazov National Medical Research Center of Cardiology

Author for correspondence.
Email: pisklova_maria@mail.ru
ORCID iD: 0000-0001-7844-3328

лаборант-исследователь ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», аспирант ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow

Natalia M. Baulina

Chazov National Medical Research Center of Cardiology

Email: pisklova_maria@mail.ru
ORCID iD: 0000-0001-8767-2958

канд. биол. наук, ст. науч. сотр. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова»

Russian Federation, Moscow

Ivan S. Kiselev

Chazov National Medical Research Center of Cardiology

Email: pisklova_maria@mail.ru
ORCID iD: 0000-0003-3366-4113

ст. науч. сотр. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова»

Russian Federation, Moscow

Dmitry A. Zateyshchikov

Chazov National Medical Research Center of Cardiology; Central State Medical Academy of the Administrative Department of the President of the Russian Federation

Email: pisklova_maria@mail.ru
ORCID iD: 0000-0001-7065-2045

д-р мед. наук, проф., лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», зав. каф. терапии, кардиологии и функциональной диагностики с курсом нефрологии ФГБУ ДПО ЦГМА

Russian Federation, Moscow; Moscow

Olga O. Favorova

Chazov National Medical Research Center of Cardiology; Pirogov Russian National Research Medical University

Email: pisklova_maria@mail.ru
ORCID iD: 0000-0002-5271-6698

д-р мед. наук, проф., гл. науч. сотр., зав. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», гл. науч. сотр. НИЛ «Медицинская геномика» Научно-исследовательского института трансляционной медицины ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow; Moscow

Olga S. Chumakova

Chazov National Medical Research Center of Cardiology; Central State Medical Academy of the Administrative Department of the President of the Russian Federation; City Clinical Hospital №17

Email: pisklova_maria@mail.ru
ORCID iD: 0000-0003-2373-1183

канд. мед. наук, лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», доц. каф. терапии, кардиологии и функциональной диагностики с курсом нефрологии ФГБУ ДПО ЦГМА, врач-кардиолог ГБУЗ «ГКБ №17»

Russian Federation, Moscow; Moscow; Moscow

References

  1. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):372-89. doi: 10.1016/j.jacc.2021.12.002
  2. Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., и др. Гипертрофическая кардиомиопатия. Клинические рекомендации. 2020. Российский кардиологический журнал. 2021;26(5):4541 [Gabrusenko SA, Gudkova AYa, Koziolova NA, et al. 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2021;26(5):4541 (in Russian)]. doi: 10.15829/1560-4071-2021-4541
  3. Seidman CE, Seidman J, Robbins J, Watkins H. Identifying Sarcomere Gene Mutations in Hypertrophic Cardiomyopathy. Circ Res. 2011;108(6):743-50. doi: 10.1161/CIRCRESAHA.110.223834
  4. Chiti E, Di Paolo M, Turillazzi E, Rocchi A. MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy. Diagnostics (Basel). 2021;11(9):1720. doi: 10.3390/diagnostics11091720
  5. Cui C, Cui Q. The relationship of human tissue microRNAs with those from body fluids. Sci Rep. 2020;10(1):5644. doi: 10.1038/s41598-020-62534-6
  6. Zhou SS, Jin JP, Wang JQ, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin. 2018;39(7):1073-84. doi: 10.1038/aps.2018.30
  7. Baulina N, Pisklova M, Kiselev I, et al. Circulating miR-499a-5p Is a Potential Biomarker of MYH7-Associated Hypertrophic Cardiomyopathy. Int J Mol Sci. 2022;23(7):3791. doi: 10.3390/ijms23073791
  8. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284
  9. Dragasis S, Vlachos K, Kariki O, et al. Atrial fibrillation in hypertrophic cardiomyopathy – A contemporary mini-review. Hellenic J Cardiol. 2022;67:66-72. doi: 10.1016/j.hjc.2022.05.002
  10. Guttmann OP, Pavlou M, O’Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017;103(9):672-8. doi: 10.1136/heartjnl-2016-309672
  11. Neubauer S, Kolm P, Ho CY, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019;74(19):2333-45. doi: 10.1016/j.jacc.2019.08.1057
  12. Cardim N, Brito D, Rocha Lopes L, et al. The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Rev Port Cardiol (Engl Ed). 2018;37(1):1-10. doi: 10.1016/j.repc.2017.08.005
  13. Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation. 2018;138(14):1387-98. doi: 10.1161/CIRCULATIONAHA.117.033200
  14. Biagini E, Pazzi C, Olivotto I, et al. Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(3):432-9. doi: 10.1016/j.amjcard.2016.05.023
  15. Dumont CA, Monserrat L, Soler R, et al. Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance. Eur Heart J. 2006;27(14):1725-31. doi: 10.1093/eurheartj/ehl101
  16. Andreeva S, Chumakova O, Karelkina E, et al. Case Report: Two New Cases of Autosomal-Recessive Hypertrophic Cardiomyopathy Associated With TRIM63-Compound Heterozygous Variant. Frontiers in Genetics. 2022;13. Available at: https://www.frontiersin.org/article/10.3389/fgene.2022.743472. Accessed: 07.05.2022.
  17. Bell ML, Buvoli M, Leinwand LA. Uncoupling of Expression of an Intronic MicroRNA and Its Myosin Host Gene by Exon Skipping. Mol Cell Biol. 2010;30(8):1937-45. doi: 10.1128/MCB.01370-09
  18. Zhang C, Zhang H, Zhao L, et al. Differential Expression of microRNAs in Hypertrophied Myocardium and Their Relationship to Late Gadolinium Enhancement, Left Ventricular Hypertrophy and Remodeling in Hypertrophic Cardiomyopathy. Diagnostics. 2022;12(8):1978. doi: 10.3390/diagnostics12081978
  19. Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022;23(2):e34-61. doi: 10.1093/ehjci/jeab154
  20. Nair N, Kumar S, Gongora E, Gupta S. Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem. 2013;376(1):33-40. doi: 10.1007/s11010-012-1546-x
  21. Wang Y, Pan W, Bai X, et al. microRNA-454-mediated NEDD4-2/TrkA/cAMP axis in heart failure: Mechanisms and cardioprotective implications. J Cell Mol Med. 2021;25(11):5082-98. doi: 10.1111/jcmm.16491
  22. Saddic LA, Chang TW, Sigurdsson MI, et al. Integrated microRNA and mRNA responses to acute human left ventricular ischemia. Physiol Genomics. 2015;47(10):455-62. doi: 10.1152/physiolgenomics.00049.2015
  23. Bi X, Zhang Y, Yu Y, et al. MiRNA-339-5p promotes isoproterenol-induced cardiomyocyte hypertrophy by targeting VCP to activate the mTOR signaling. Cell Biol Int. 2022;46(2):288-99. doi: 10.1002/cbin.11731
  24. Shi L, Zhang Y, Zhang J, et al. MiR-339 is a potential biomarker of coronary heart disease to aggravate oxidative stress through Nrf2/FOXO3 targeting Sirt2. Ann Palliat Med. 2021;10(3):2596609. doi: 10.21037/apm-20-603
  25. Gartz M, Beatka M, Prom MJ, et al. Cardiomyocyte-produced miR-339-5p mediates pathology in Duchenne muscular dystrophy cardiomyopathy. Hum Mol Genet. 2021;30(23):2347-61. doi: 10.1093/hmg/ddab199

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies